Latch Bio, a San Francisco, CA-based company building data infrastructure for biocomputing, closed a $5m seed funding round.
The round was led by Lux Capital with participation from General Catalyst, Haystack, Fifty Years, and Asimov co-founder and CEO, Alec Nielsen, Ph.D.
Founded in 2021 by Alfredo Andere, Kyle Giffin, and Kenny Workman who met as undergraduates at the University of California, Berkeley, Latch Bio is building a web-based platform which enables any biologist to analyze CRISPR data without any code or cloud infrastructure setup.
Using the platform, any researcher can now create a centralized one-stop-shop for storing, transforming and visualizing their data without writing any code. Through the plugins, users can import files from their existing data stack including Amazon S3, Benchling, and Illumina’s BaseSpace. Biologists have access to dozens of workflows including CRISPResso, MAGeCK, CasTLE, Cas.py, MultiQC, and CasOffinder, among others. After performing a specific workflow, users can further interrogate the results using the built-in genomic visualizer and quality controls. The platform is offered free to academic research users.
FinSMEs
04/10/2021